Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 27, 2017

DrugPatentWatch Database Preview

Dihydroergotamine mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for dihydroergotamine mesylate and what is the scope of patent protection?

Dihydroergotamine mesylate
is the generic ingredient in four branded drugs marketed by Valeant, West-ward Pharms Int, Paddock Llc, and Novartis, and is included in five NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for dihydroergotamine mesylate. Four suppliers are listed for this compound.

Summary for Generic Name: dihydroergotamine mesylate

Drug Master File Entries: see list5
Suppliers / Packagers: see list4
Bulk Api Vendors: see list49
Clinical Trials: see list179
Patent Applications: see list831
Therapeutic Class:Antimigraine Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:dihydroergotamine mesylate at DailyMed

Pharmacology for Ingredient: dihydroergotamine mesylate

Drug ClassErgotamine Derivative
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
D.H.E. 45
dihydroergotamine mesylate
INJECTABLE;INJECTION005929-001Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-002Nov 30, 1984DISCNNoNo► Subscribe► Subscribe
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-001Nov 30, 1984DISCNNoNo► Subscribe► Subscribe
dihydroergotamine mesylate
SPRAY, METERED;NASAL020148-001Dec 8, 1997RXYesYes► Subscribe► Subscribe
Paddock Llc
dihydroergotamine mesylate
INJECTABLE;INJECTION040475-001Apr 28, 2003APRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Formulary management
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus